Your browser doesn't support javascript.
loading
A trichostatin A expression signature identified by TempO-Seq targeted whole transcriptome profiling.
Yeakley, Joanne M; Shepard, Peter J; Goyena, Diana E; VanSteenhouse, Harper C; McComb, Joel D; Seligmann, Bruce E.
Affiliation
  • Yeakley JM; BioSpyder Technologies, Incorporated, Carlsbad, California, United States of America.
  • Shepard PJ; BioSpyder Technologies, Incorporated, Carlsbad, California, United States of America.
  • Goyena DE; BioSpyder Technologies, Incorporated, Carlsbad, California, United States of America.
  • VanSteenhouse HC; BioSpyder Technologies, Incorporated, Carlsbad, California, United States of America.
  • McComb JD; BioSpyder Technologies, Incorporated, Carlsbad, California, United States of America.
  • Seligmann BE; BioSpyder Technologies, Incorporated, Carlsbad, California, United States of America.
PLoS One ; 12(5): e0178302, 2017.
Article in En | MEDLINE | ID: mdl-28542535
ABSTRACT
The use of gene expression signatures to classify compounds, identify efficacy or toxicity, and differentiate close analogs relies on the sensitivity of the method to identify modulated genes. We used a novel ligation-based targeted whole transcriptome expression profiling assay, TempO-Seq®, to determine whether previously unreported compound-responsive genes could be identified and incorporated into a broad but specific compound signature. TempO-Seq exhibits 99.6% specificity, single cell sensitivity, and excellent correlation with fold differences measured by RNA-Seq (R2 = 0.9) for 20,629 targets. Unlike many expression assays, TempO-Seq does not require RNA purification, cDNA synthesis, or capture of targeted RNA, and lacks a 3' end bias. To investigate the sensitivity of the TempO-Seq assay to identify significantly modulated compound-responsive genes, we derived whole transcriptome profiles from MCF-7 cells treated with the histone deacetylase inhibitor Trichostatin A (TSA) and identified more than 9,000 differentially expressed genes. The TSA profile for MCF-7 cells overlapped those for HL-60 and PC-3 cells in the Connectivity Map (cMAP) database, suggesting a common TSA-specific expression profile independent of baseline gene expression. A 43-gene cell-independent TSA signature was extracted from cMAP and confirmed in TempO-Seq MCF-7 data. Additional genes that were not previously reported to be TSA responsive in the cMAP database were also identified. TSA treatment of 5 cell types revealed 1,136 differentially expressed genes in common, including 785 genes not previously reported to be TSA responsive. We conclude that TSA induces a specific expression signature that is consistent across widely different cell types, that this signature contains genes not previously associated with TSA responses, and that TempO-Seq provides the sensitive differential expression detection needed to define such compound-specific, cell-independent, changes in expression.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Gene Expression Profiling / Hydroxamic Acids Type of study: Diagnostic_studies / Prognostic_studies Limits: Humans Language: En Journal: PLoS One Journal subject: CIENCIA / MEDICINA Year: 2017 Document type: Article Affiliation country: Estados Unidos

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Gene Expression Profiling / Hydroxamic Acids Type of study: Diagnostic_studies / Prognostic_studies Limits: Humans Language: En Journal: PLoS One Journal subject: CIENCIA / MEDICINA Year: 2017 Document type: Article Affiliation country: Estados Unidos